哈尔滨医药2024，Vol.44Issue(2)：131-135,5.DOI:10.3969/j.issn.1001-8131.2024.02.045
达格列净治疗心力衰竭的研究进展
Dapagliflozin In The Treatment of Heart Failure
肇启迪 1黄幸涛1
作者信息
- 1. 哈尔滨医科大学附属第二医院,哈尔滨 黑龙江 150070
- 折叠
摘要
Abstract
Heart failure is the final stage of various cardiovascular diseases.Cardiac stimulant,diuretic,vasodilators com-bined with sympathetic nerve inhibition and renin-angiotensin-aldosterone system inhibition are the means of clinical heart failure treating.To a certain extent,they delay the progression of heart failure.But the recurrence rate and mortality of heart failure patients are still very high.In recent years,with the widespread use of the diabetes drug-dapagliflozin,we have found that it can benefit patients with heart failure.Dapagliflozin was approved for the treatment of heart failure in February 2021 and has been widely used in clinical practice.A review of the latest research progress of the sodium glucose cotransporter-2 inhibitor dapagliflozin in the field of heart failure is presented.关键词
达格列净/心力衰竭/钠葡萄糖共转运体-2抑制剂Key words
Dapagliflozin/Heart Failure/sodium-dependent glucose transporters 2 Inhibitor分类
医药卫生引用本文复制引用
肇启迪,黄幸涛..达格列净治疗心力衰竭的研究进展[J].哈尔滨医药,2024,44(2):131-135,5.
